Robert Goerss
Corneal and Contact Management · O Fallon, MONPI 1386640050
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.1% of the total across 97 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 15 manufacturers reported payments, led by Alcon at 25.5% of the total. Among corneal and contact management clinicians in MO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 97 payments — averaging $36.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$906
- Coopervision Inc.$622
- Bausch & Lomb Americas Inc.$568
- Johnson & Johnson Vision Care, Inc.$404
- Tarsus Pharmaceuticals, Inc.$340
- Bausch & Lomb, A Division Of Bausch Health US, LLC$293
- plus $417 from 9 others
What the payments were for
- Food & beverage$3,51999%
- Entertainment$311%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 19 | $906 |
| Coopervision Inc. | 17 | $622 |
| Bausch & Lomb Americas Inc. | 7 | $568 |
| Johnson & Johnson Vision Care, Inc. | 18 | $404 |
| Tarsus Pharmaceuticals, Inc. | 9 | $340 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 14 | $293 |
| Sun Pharmaceutical Industries Inc. | 3 | $170 |
| AbbVie | 2 | $75 |
| Lombart Brothers, Inc. | 1 | $34 |
| Novartis | 2 | $32 |
| Optos, Inc. | 1 | $31 |
| Johnson & Johnson Surgical Vision, Inc. | 1 | $27 |
| Kala Pharmaceuticals, Inc. | 1 | $22 |
| Synergeyes, Inc. | 1 | $15 |
| Quidel Corporation | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XDEMVY$243
- INFUSE$237
- Precision 1$144
- DAILIES$130
- TOTAL30$126
- MIEBO$125
- DAILIES TOTAL1$119
- CEQUA$114
How this compares
$3,550 in reported general payments places this provider in the 95th percentile of 22 corneal and contact management providers in Missouri.
See all corneal and contact management providers in Missouri →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XdemvyLotilaner | 25 | $48,378 |
| LumiganBimatoprost | 45 | $18,298 |
| MieboPerfluorohexyloctane/Pf | 18 | $13,402 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 19 | $3,756 |
| CombiganBrimonidine Tartrate/Timolol | 15 | $3,482 |
| Timolol Maleate | 48 | $1,426 |
| Latanoprost | 170 | $1,412 |
| Doxycycline Hyclate | 21 | $923 |
| Tobramycin-DexamethasoneTobramycin/Dexamethasone | 17 | $460 |
| Prednisolone Acetate | 14 | $449 |
| ValacyclovirValacyclovir Hcl | 16 | $420 |
| Dorzolamide Hcl | 14 | $225 |
| Brimonidine Tartrate | 11 | $78 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Tarsus Pharmaceuticals, Inc.Xdemvy | $340 | $48,37825 claims |
| AbbVieLumigan, Combigan | $75 | $21,78060 claims |
| Bausch & Lomb Americas Inc.Miebo | $568 | $13,40218 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 22 corneal and contact management providers in Missouri.
Other corneal and contact management in O Fallon
- Jessica TuSt. Louis$12K
- Charles BruceWashington$3K
- Thomas AltenberndSaint Louis$3K
- Frank BierManchester$2K
- Jessica WeisCreve Coeur$2K
- Kevin LydonSaint Peters$2K
- Cathy PhillipsPacific$1K
- Gary DelanceyEllisville$1K
- Timothy LischweOsage Beach$1K
- Amir JalaliMexico$993
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.